AtaiBeckley Inc. 4

Laurent Fischer had all outstanding AtaiBeckley Inc. stock options (totaling 430,968 underlying shares) cancelled for cash and CVRs upon Eli Lilly’s acquisition at $6.75 per share.

On September 11, 2026, in connection with the closing of Eli Lilly and Company’s cash acquisition of AtaiBeckley Inc., all of Laurent Fischer’s outstanding stock options in AtaiBeckley were automatically cancelled and converted into the right to receive cash based on the $6.75 per share merger consideration in excess of each option’s exercise price, plus one contingent value right (CVR) per underlying share with potential additional cash of up to $2.50 per CVR upon achievement of specified milestones. Specifically, options for 206,000 shares at a $1.34 exercise price, 103,000 shares at a $2.25 exercise price, and 121,968 shares at a $4.50 exercise price were terminated, and the Form 4 reports zero derivative and non-derivative holdings afterward, reflecting the cash-out of his equity awards as the company became a wholly owned subsidiary of Eli Lilly.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036384

Alert Tier

6